Detalhe da pesquisa
1.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Lancet Oncol
; 23(12): 1571-1582, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370716
2.
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Int J Cancer
; 147(1): 160-169, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724170
3.
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.
Oncology
; 94 Suppl 1: 34-44, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30041178
4.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2â×â2 factorial, randomised phase 3 trial.
Lancet
; 385(9980): 1863-72, 2015 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25740286
5.
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
EClinicalMedicine
; 70: 102501, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685923
6.
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
J Clin Oncol
; 41(32): 4976-4981, 2023 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748109
7.
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
EClinicalMedicine
; 59: 101931, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256095
8.
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Clin Cancer Res
; 29(24): 5217-5226, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37888299
9.
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Cancers (Basel)
; 16(1)2023 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201545
10.
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.
NPJ Breast Cancer
; 7(1): 82, 2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34183674
11.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Care (Basel)
; 15(1): 30-37, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32231495
12.
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(94): 36720-36721, 2018 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30613355
13.
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(77): 34639-34640, 2018 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30349655
14.
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(61): 31877-31887, 2018 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30159129
15.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Eur J Cancer
; 71: 34-42, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27951450